News

Filter

1 to 9 of 163 results

NICE gives go ahead for Xolair to treat potentially disabling skin condition

NICE gives go ahead for Xolair to treat potentially disabling skin condition

11-03-2015

The medicines cost watchdog the National Institute of Health and Care Excellence (NICE) has recommended…

DermatologicalsNovartisPharmaceuticalPricingRegulationUKXolair

European Commission approves Actavis’ Xydalba

02-03-2015

The European Commission has granted Ireland-headquartered Actavis' subsidiary Durata Therapeutics International…

ActavisAngeliniAntibiotics and Infectious diseasesDalvanceDermatologicalsDurata TherapeuticsEuropePharmaceuticalXydalba

Dupilumab Phase IIb shows improvement in patient-reported outcomes for dermatitis

Dupilumab Phase IIb shows improvement in patient-reported outcomes for dermatitis

23-02-2015

A Phase IIb study of dupilumab, from Sanofi and Regeneron, has shown that the drug improved patient-reported…

DermatologicalsdupilumabPharmaceuticalRegeneronResearchSanofi

Ferrer licenses Canadian rights for ozenoxacin to Cipher Pharma

07-01-2015

Privately-held Spanish pharmaceutical company Ferrer says it has licensed commercialization rights for…

CanadaCipher PharmaceuticalsDermatologicalsFerrerLicensingOzenoxacinPharmaceutical

Leo Pharma files for US approval of first aerosol foam for psoriasis

06-01-2015

Independent Danish dermatology specialist Leo Pharma has submitted a New Drug Application to the US Food…

BetamethasonecalcipotrienecalcipotriolDermatologicalsLEO PharmaPharmaceuticalRegulationUSA

FDA approves Teva’s Granix and Galderma’s Soolantra

FDA approves Teva’s Granix and Galderma’s Soolantra

24-12-2014

The Food and Drug Administration has approved Israeli generics giant Teva Pharmaceutical Industries’…

DermatologicalsGaldermaGranixIvermectinPharmaceuticalRare diseasesRegulationSoolantraTeva Pharmaceutcal IndustriesUSA

Novartis' Cosentyx demonstrates superiority to Stelara in head-to-head psoriasis study

Novartis' Cosentyx demonstrates superiority to Stelara in head-to-head psoriasis study

15-12-2014

Swiss drug major Novartis announced that the Phase IIIb CLEAR study for Cosentyx (secukinumab) met its…

CosentyxDermatologicalsNovartisPharmaceuticalResearchSwitzerland

Amgen/AstraZeneca's brodalumab trial meets primary endpoints for moderate-to-severe plaque psoriasis

Amgen/AstraZeneca's brodalumab trial meets primary endpoints for moderate-to-severe plaque psoriasis

26-11-2014

USA-based Amgen, the world’s leading independent biotech firm, and Anglo-Swedish drug major AstraZeneca…

AmgenAstraZenecabrodalumabDermatologicalsPharmaceuticalResearch

1 to 9 of 163 results

Back to top